omarigliptin   Click here for help

GtoPdb Ligand ID: 8402

Synonyms: MK-3102 | MK3102
Compound class: Synthetic organic
Comment: Omarigliptin is an investigational long-acting inhibitor of dipeptidyl peptidase 4 (DPP4) [1]. The first DPP4 inhibitor to be clinically approved was sitagliptin. This has subsequently been joined by several more drugs such as vildagliptin, saxagliptin, linagliptin and alogliptin.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 3
Topological polar surface area 98.83
Molecular weight 398.12
XLogP 0.93
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Fc1ccc(c(c1)C1OCC(CC1N)N1Cc2c(C1)cn(n2)S(=O)(=O)C)F
Isomeric SMILES Fc1ccc(c(c1)[C@H]1OC[C@@H](C[C@@H]1N)N1Cc2c(C1)cn(n2)S(=O)(=O)C)F
InChI InChI=1S/C17H20F2N4O3S/c1-27(24,25)23-7-10-6-22(8-16(10)21-23)12-5-15(20)17(26-9-12)13-4-11(18)2-3-14(13)19/h2-4,7,12,15,17H,5-6,8-9,20H2,1H3/t12-,15+,17-/m1/s1
InChI Key MKMPWKUAHLTIBJ-ISTRZQFTSA-N
No information available.
Summary of Clinical Use Click here for help
Many Phase 3 trials have been carried out to evaluate omarigliptin (using its research code MK-3102) as a treatment for type 2 diabetes mellitus (T2DM). Click here to link to ClinicalTrials.gov's complete list of Phase 3 MK-3102 trials.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Inhibition of DPP4 extends the circulating half-life of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Increasing circulating GLP-1 and GIP, helps to improve glucose control in patients with type 2 diabetes.